Silence Therapeutics plc Share Price Other OTC
Stocks
SLNCF
GB00B9GTXM62
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 348M 467M 408M 376M 660M 44.49B 671M 4.5B 1.77B 21.92B 1.75B 1.71B 75.35B | P/E 2026 * |
-16.5x | P/E 2027 * | -14.7x |
|---|---|---|---|---|---|
| Enterprise Value | 201M 270M 236M 218M 382M 25.75B 388M 2.6B 1.02B 12.69B 1.01B 992M 43.61B | EV / Sales 2026 * |
80.6x | EV / Sales 2027 * | 28.5x |
| Free-Float |
69.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| 1 day | +8.84% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 30/11/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 31/01/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 20/06/2018 |
Iain Ross
CHM | Chairman | 72 | 31/12/2003 |
Tim McInerney
BRD | Director/Board Member | 65 | 04/05/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.84% | -.--% | - | - | 466M | |
| +0.58% | +2.06% | +2.92% | +10.86% | 50.44B | |
| -1.91% | -1.58% | +385.68% | +587.19% | 40.63B | |
| -0.69% | +0.77% | +25.39% | -5.41% | 34.88B | |
| -1.51% | -3.67% | +17.64% | +54.83% | 33.67B | |
| +1.21% | -0.79% | +4.46% | +35.18% | 26.29B | |
| -2.19% | +0.06% | - | - | 17.11B | |
| -0.05% | -5.47% | +62.74% | +120.93% | 15.29B | |
| -8.01% | -29.18% | +39.00% | +41.00% | 10.62B | |
| +0.23% | -0.58% | +13.76% | +21.11% | 13.74B | |
| Average | -0.33% | -2.12% | +68.95% | +108.21% | 26.96B | |
| Weighted average by Cap. | -0.82% | -0.03% | +84.13% | +131.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.5M 3.35M 2.93M 2.7M 4.74M 319M 4.81M 32.28M 12.68M 157M 12.57M 12.3M 541M | 3.44M 4.62M 4.04M 3.73M 6.53M 440M 6.64M 44.51M 17.48M 217M 17.34M 16.96M 746M |
| Net income | -50.34M -67.56M -59.09M -54.5M -95.52M -6.44B -97.13M -651M -256M -3.17B -254M -248M -10.91B | -84.67M -114M -99.38M -91.67M -161M -10.84B -163M -1.1B -430M -5.34B -427M -417M -18.35B |
| Net Debt | -146M -197M -172M -159M -278M -18.74B -283M -1.89B -744M -9.23B -738M -722M -31.74B | -249M -335M -293M -270M -473M -31.92B -481M -3.23B -1.27B -15.73B -1.26B -1.23B -54.07B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
